Maruyama H - Search Results

1

Maxacalcitol is a possible less phosphatemic vitamin D analog.

Kazama JJ, Maruyama H, Narita I, Gejyo F. Kazama JJ, et al. Among authors: maruyama h. Ther Apher Dial. 2005 Aug;9(4):352-4. doi: 10.1111/j.1744-9987.2005.00296.x. Ther Apher Dial. 2005. PMID: 16076381

2

Clinical studies of destructive spondyloarthropathy in long-term hemodialysis patients.

Maruyama H, Gejyo F, Arakawa M. Maruyama H, et al. Nephron. 1992;61(1):37-44. doi: 10.1159/000186832. Nephron. 1992. PMID: 1528338

3

[Dialysis amyloidosis].

Gejyo F, Maruyama S, Maruyama H, Homma N, Arakawa M. Gejyo F, et al. Among authors: maruyama s, maruyama h. Nihon Rinsho. 1991 Apr;49(4):821-5. Nihon Rinsho. 1991. PMID: 2072537 Review. Japanese. No abstract available.

4

Effects of a new adsorbent column for removing beta-2-microglobulin from circulating blood of dialysis patients.

Homma N, Gejyo F, Hasegawa S, Teramura T, Ei I, Maruyama H, Arakawa M. Homma N, et al. Among authors: maruyama h. Contrib Nephrol. 1995;112:164-71. doi: 10.1159/000424105. Contrib Nephrol. 1995. PMID: 7554988 Clinical Trial. No abstract available.

5

[Amyloidosis associated with long-term dialysis].

Gejyo F, Maruyama H, Arakawa M. Gejyo F, et al. Among authors: maruyama h. Nihon Jinzo Gakkai Shi. 1995 Jan;37(1):1-6. Nihon Jinzo Gakkai Shi. 1995. PMID: 7699947 Review. Japanese.

6

Acquired type II protein C deficiency in a long-term hemodialysis patient.

Maruyama H, Gejyo F, Hanano M, Arakawa M. Maruyama H, et al. Nephron. 1994;66(3):348-50. doi: 10.1159/000187835. Nephron. 1994. PMID: 8190190

7

Requiring higher doses of erythropoietin suggests pregnancy in hemodialysis patients.

Maruyama H, Shimada H, Obayashi H, Nakamaru T, Miyakawa Y, Goto S, Ogihara T, Takakuwa K, Tanaka K, Kishimoto H, Yuasa Y, Sakai S, Okajima H, Suzuki S, Arakawa M. Maruyama H, et al. Nephron. 1998 Aug;79(4):413-9. doi: 10.1159/000045086. Nephron. 1998. PMID: 9689156 Clinical Trial.

8

Thoracic aortic dissection in a patient with autosomal dominant polycystic kidney disease treated with maintenance hemodialysis.

Osawa Y, Omori S, Nagai M, Obayashi H, Maruyama H, Gejyo F. Osawa Y, et al. Among authors: maruyama h. J Nephrol. 2000 May-Jun;13(3):193-5. J Nephrol. 2000. PMID: 10928295

9

Reduction of circulating beta2-microglobulin level for the treatment of dialysis-related amyloidosis.

Kazama JJ, Maruyama H, Gejyo F. Kazama JJ, et al. Among authors: maruyama h. Nephrol Dial Transplant. 2001;16 Suppl 4:31-5. doi: 10.1093/ndt/16.suppl_4.31. Nephrol Dial Transplant. 2001. PMID: 11402095 Review.

10

Osteoclastogenesis and osteoclast activation in dialysis-related amyloid osteopathy.

Kazama JJ, Maruyama H, Gejyo F. Kazama JJ, et al. Among authors: maruyama h. Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S156-60. doi: 10.1053/ajkd.2001.27427. Am J Kidney Dis. 2001. PMID: 11576944 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results